Journal Logo

Articles by C. Gakiopoulou

AN EARLY, WITHIN THE FIRST MONTH, AND DEEP RESPONSE, SHOULD BE THE GOAL OF THERAPY IN AL AMYLOIDOSIS: PS1378

Kastritis, E.; Karatrasoglou, E. A.; Dialoupi, I.; More

HemaSphere. 3:630-631, June 2019.

CONSOLIDATION WITH A SHORT COURSE OF DARATUMUMAB CAN SIGNIFICANTLY IMPROVE COMPLETE RESPONSE RATES IN PATIENTS WITH AL AMYLOIDOSIS OR LCDD: PS1392

Kastritis, E.; Gavriatopoulou, M.; Kostopoulos, I. V.; More

HemaSphere. 3:638-639, June 2019.

PRIMARY TREATMENT OF LIGHT CHAIN (AL) AMYLOIDOSIS WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (VRD): PS1393

Kastritis, E.; Dialoupi, I.; Gavriatopoulou, M.; More

HemaSphere. 3:639, June 2019.